213 related articles for article (PubMed ID: 31787505)
1. Possible therapeutic applicability of galectin-9 in cutaneous T-cell lymphoma.
Nakajima R; Miyagaki T; Kamijo H; Oka T; Shishido-Takahashi N; Suga H; Sugaya M; Sato S
J Dermatol Sci; 2019 Dec; 96(3):134-142. PubMed ID: 31787505
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the Effect of Gentian Violet on Apoptosis and Proliferation in Cutaneous T-Cell Lymphoma in an In Vitro Study.
Wu J; Wood GS
JAMA Dermatol; 2018 Oct; 154(10):1191-1198. PubMed ID: 30167641
[TBL] [Abstract][Full Text] [Related]
3. Expression of immune checkpoint molecules of T cell immunoglobulin and mucin protein 3/galectin-9 for NK cell suppression in human gastrointestinal stromal tumors.
Komita H; Koido S; Hayashi K; Kan S; Ito M; Kamata Y; Suzuki M; Homma S
Oncol Rep; 2015 Oct; 34(4):2099-105. PubMed ID: 26239720
[TBL] [Abstract][Full Text] [Related]
4. Tim-3 signaling blockade with α-lactose induces compensatory TIGIT expression in Plasmodium berghei ANKA-infected mice.
Zhang Y; Jiang N; Zhang T; Chen R; Feng Y; Sang X; Yang N; Chen Q
Parasit Vectors; 2019 Nov; 12(1):534. PubMed ID: 31711531
[TBL] [Abstract][Full Text] [Related]
5. The Tim-3/galectin-9 pathway involves in the homeostasis of hepatic Tregs in a mouse model of concanavalin A-induced hepatitis.
Ju Y; Shang X; Liu Z; Zhang J; Li Y; Shen Y; Liu Y; Liu C; Liu B; Xu L; Wang Y; Zhang B; Zou J
Mol Immunol; 2014 Mar; 58(1):85-91. PubMed ID: 24333756
[TBL] [Abstract][Full Text] [Related]
6. Galectin-9 in cancer therapy.
Fujihara S; Mori H; Kobara H; Rafiq K; Niki T; Hirashima M; Masaki T
Recent Pat Endocr Metab Immune Drug Discov; 2013 May; 7(2):130-7. PubMed ID: 23514536
[TBL] [Abstract][Full Text] [Related]
7. Proapoptotic and antiapoptotic markers in cutaneous T-cell lymphoma skin infiltrates and lymphomatoid papulosis.
Nevala H; Karenko L; Vakeva L; Ranki A
Br J Dermatol; 2001 Dec; 145(6):928-37. PubMed ID: 11899146
[TBL] [Abstract][Full Text] [Related]
8. Galectin-9 and T cell immunoglobulin mucin-3 pathway is a therapeutic target for type 1 diabetes.
Kanzaki M; Wada J; Sugiyama K; Nakatsuka A; Teshigawara S; Murakami K; Inoue K; Terami T; Katayama A; Eguchi J; Akiba H; Yagita H; Makino H
Endocrinology; 2012 Feb; 153(2):612-20. PubMed ID: 22186414
[TBL] [Abstract][Full Text] [Related]
9. Avicin D selectively induces apoptosis and downregulates p-STAT-3, bcl-2, and survivin in cutaneous T-cell lymphoma cells.
Zhang C; Li B; Gaikwad AS; Haridas V; Xu Z; Gutterman JU; Duvic M
J Invest Dermatol; 2008 Nov; 128(11):2728-2735. PubMed ID: 18496567
[TBL] [Abstract][Full Text] [Related]
10. Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma.
Jain S; Stroopinsky D; Yin L; Rosenblatt J; Alam M; Bhargava P; Clark RA; Kupper TS; Palmer K; Coll MD; Rajabi H; Pyzer A; Bar-Natan M; Luptakova K; Arnason J; Joyce R; Kufe D; Avigan D
Blood; 2015 Jul; 126(3):354-62. PubMed ID: 26048911
[TBL] [Abstract][Full Text] [Related]
11. Exogenous expression of SAMHD1 inhibits proliferation and induces apoptosis in cutaneous T-cell lymphoma-derived HuT78 cells.
Kodigepalli KM; Li M; Liu SL; Wu L
Cell Cycle; 2017 Jan; 16(2):179-188. PubMed ID: 27929746
[TBL] [Abstract][Full Text] [Related]
12. Expression of human T cell immunoglobulin domain and mucin-3 (TIM-3) and TIM-3 ligands in peripheral blood from patients with systemic lupus erythematosus.
Jiao Q; Qian Q; Zhao Z; Fang F; Hu X; An J; Wu J; Liu C
Arch Dermatol Res; 2016 Oct; 308(8):553-61. PubMed ID: 27394439
[TBL] [Abstract][Full Text] [Related]
13. Combined inhibition of Bcl-2 and NFκB synergistically induces cell death in cutaneous T-cell lymphoma.
Froehlich TC; Müller-Decker K; Braun JD; Albrecht T; Schroeder A; Gülow K; Goerdt S; Krammer PH; Nicolay JP
Blood; 2019 Aug; 134(5):445-455. PubMed ID: 31167801
[TBL] [Abstract][Full Text] [Related]
14. BAFF levels are increased in lesional skin and sera in patients with cutaneous T-cell lymphoma.
Ohmatsu H; Sugaya M; Miyagaki T; Suga H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Br J Dermatol; 2012 Aug; 167(2):359-67. PubMed ID: 22512719
[TBL] [Abstract][Full Text] [Related]
15. Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma.
Li H; Wu K; Tao K; Chen L; Zheng Q; Lu X; Liu J; Shi L; Liu C; Wang G; Zou W
Hepatology; 2012 Oct; 56(4):1342-51. PubMed ID: 22505239
[TBL] [Abstract][Full Text] [Related]
16. YKL-40 Promotes Proliferation of Cutaneous T-Cell Lymphoma Tumor Cells through Extracellular Signal-Regulated Kinase Pathways.
Suzuki H; Boki H; Kamijo H; Nakajima R; Oka T; Shishido-Takahashi N; Suga H; Sugaya M; Sato S; Miyagaki T
J Invest Dermatol; 2020 Apr; 140(4):860-868.e3. PubMed ID: 31622598
[TBL] [Abstract][Full Text] [Related]
17. The Tim-3-Galectin-9 Pathway and Its Regulatory Mechanisms in Human Breast Cancer.
Yasinska IM; Sakhnevych SS; Pavlova L; Teo Hansen Selnø A; Teuscher Abeleira AM; Benlaouer O; Gonçalves Silva I; Mosimann M; Varani L; Bardelli M; Hussain R; Siligardi G; Cholewa D; Berger SM; Gibbs BF; Ushkaryov YA; Fasler-Kan E; Klenova E; Sumbayev VV
Front Immunol; 2019; 10():1594. PubMed ID: 31354733
[TBL] [Abstract][Full Text] [Related]
18. Nonsteroidal anti-inflammatory drugs induce apoptosis in cutaneous T-cell lymphoma cells and enhance their sensitivity for TNF-related apoptosis-inducing ligand.
Braun FK; Al-Yacoub N; Plötz M; Möbs M; Sterry W; Eberle J
J Invest Dermatol; 2012 Feb; 132(2):429-39. PubMed ID: 22011910
[TBL] [Abstract][Full Text] [Related]
19. Peripheral blood TIM-3 positive NK and CD8+ T cells throughout pregnancy: TIM-3/galectin-9 interaction and its possible role during pregnancy.
Meggyes M; Miko E; Polgar B; Bogar B; Farkas B; Illes Z; Szereday L
PLoS One; 2014; 9(3):e92371. PubMed ID: 24651720
[TBL] [Abstract][Full Text] [Related]
20. TIM-3 does not act as a receptor for galectin-9.
Leitner J; Rieger A; Pickl WF; Zlabinger G; Grabmeier-Pfistershammer K; Steinberger P
PLoS Pathog; 2013 Mar; 9(3):e1003253. PubMed ID: 23555261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
